Special issue on Epithelial Ovarian Cancer Treatment: Integrating Molecular Targeting

Posted On 2014-11-18 17:41:56

Topic: Epithelial Ovarian Cancer Treatment: Integrating Molecular Targeting
Guest editors: Franco Muggia & Eleonora Teplinsky, New York University Langone Medical Center, New York, USA

Epithelial ovarian cancer and related cancers arising in extrauterine Mullerian epithelium are generally chemosensitive, particularly to the platinum drugs cisplatin and carboplatin that form the backbone of first-line treatments upon diagnosis even at early stages. Doublets of platinums with paclitaxel have represented the standard-of-care since the late 1990s, with further notable advances taking place by intraperitoneal administration (in Gynecologic Oncology Group studies) after optimal surgical cytoreduction is achieved, and by divided doses of paclitaxel (in a Japanese GOG study).

Adding another agent to improve on these results has otherwise proven to be quite challenging. Nevertheless, continued forays into introducing ‘targeted therapies’ are beginning to bear fruit, and form part of this Translational Cancer Research special issue on “Epithelial Ovarian Cancer Treatment: Integrating Molecular Targeting” to be published in February 2015, with Drs. Franco Muggia and Eleonora Teplinsky from Perlmutter Cancer Center at the NYU Langone Medical Center, USA serving as guest editors. The purpose of this issue is to provide a glimpse of where the field is moving, and their successes to date.

Outline

Introduction: moving beyond chemotherapy
Franco Muggia, MD, Perlmutter Cancer Center at the NYU Langone Medical Center, USA

Pathogenesis of Mullerian epithelial cancer
Louis Dubeau, MD, PhD, Brigham and Women’s Hospital and University of Southern California, USA

Animal models of ovarian cancer
Daniela Dinulescu, PhD, Brigham and Women’s Hospital, USA

Low grade serous, mucinous and spectrum of molecular subtypes
David Gershenson, MD, MD Anderson Cancer Center, USA

Targeting EGFR and Her2
Eleonora Teplinsky, MD, New York University Langone Medical Center, New York, USA

Targeting DNA repair: PARP inhibitors
Bhavana Pothuri, MD, New York University Langone Medical Center, New York, USA

Targeting the folate receptor
James O’Leary, MD, ImmunoGen, Inc.

Targeting the mTOR/PI3k pathway
Fernanda Musa, MD and Robert Schneider, PhD, New York University Langone Medical Center, New York, USA

Modulation of intraperitoneal chemotherapy
Maryann Kwa, MD, and Danielle Jandial, MD, New York University Langone Medical Center and University of California, USA

Integrating new drugs with taxanes and platinums: opportunities and challenges
David Kudlowitz, MD, Eleonora Teplinsky, MD, and Franco Muggia, MD, New York University Langone Medical Center, New York, USA

The Tumor Cancer Genome Atlas (TCGA) study of high grade serous carcinomas and overview of studies on other high-grade molecular subtypes
Claire Verschraegen, University of Vermont Cancer Center, USA

Targeting angiogenesis: VEGF and related signaling pathways
Robert Coleman, MD Anderson Cancer Center, USA